Myriad Genetics Statistics
Total Valuation
Myriad Genetics has a market cap or net worth of $683.91 million. The enterprise value is $721.81 million.
Important Dates
The next estimated earnings date is Tuesday, May 6, 2025, after market close.
| Earnings Date | May 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Myriad Genetics has 92.17 million shares outstanding. The number of shares has increased by 9.42% in one year.
| Current Share Class | 92.17M |
| Shares Outstanding | 92.17M |
| Shares Change (YoY) | +9.42% |
| Shares Change (QoQ) | +0.22% |
| Owned by Insiders (%) | 2.45% |
| Owned by Institutions (%) | 100.06% |
| Float | 89.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 94.26 |
| PS Ratio | 0.80 |
| Forward PS | 0.79 |
| PB Ratio | 0.97 |
| P/TBV Ratio | 4.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.86 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.82, with a Debt / Equity ratio of 0.20.
| Current Ratio | 1.82 |
| Quick Ratio | 1.36 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -31.43 |
Financial Efficiency
Return on equity (ROE) is -17.15% and return on invested capital (ROIC) is -6.19%.
| Return on Equity (ROE) | -17.15% |
| Return on Assets (ROA) | -5.06% |
| Return on Invested Capital (ROIC) | -6.19% |
| Return on Capital Employed (ROCE) | -10.19% |
| Revenue Per Employee | $310,222 |
| Profits Per Employee | -$47,148 |
| Employee Count | 2,700 |
| Asset Turnover | 0.77 |
| Inventory Turnover | 10.19 |
Taxes
In the past 12 months, Myriad Genetics has paid $3.80 million in taxes.
| Income Tax | 3.80M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.17% in the last 52 weeks. The beta is 1.87, so Myriad Genetics's price volatility has been higher than the market average.
| Beta (5Y) | 1.87 |
| 52-Week Price Change | -60.17% |
| 50-Day Moving Average | 9.95 |
| 200-Day Moving Average | 18.14 |
| Relative Strength Index (RSI) | 29.30 |
| Average Volume (20 Days) | 1,386,007 |
Short Selling Information
The latest short interest is 5.16 million, so 5.60% of the outstanding shares have been sold short.
| Short Interest | 5.16M |
| Short Previous Month | 5.36M |
| Short % of Shares Out | 5.60% |
| Short % of Float | 5.74% |
| Short Ratio (days to cover) | 5.46 |
Income Statement
In the last 12 months, Myriad Genetics had revenue of $837.60 million and -$127.30 million in losses. Loss per share was -$1.41.
| Revenue | 837.60M |
| Gross Profit | 585.40M |
| Operating Income | -88.00M |
| Pretax Income | -156.60M |
| Net Income | -127.30M |
| EBITDA | -26.80M |
| EBIT | -88.00M |
| Loss Per Share | -$1.41 |
Full Income StatementBalance Sheet
The company has $102.40 million in cash and $140.30 million in debt, giving a net cash position of -$37.90 million or -$0.41 per share.
| Cash & Cash Equivalents | 102.40M |
| Total Debt | 140.30M |
| Net Cash | -37.90M |
| Net Cash Per Share | -$0.41 |
| Equity (Book Value) | 701.10M |
| Book Value Per Share | 7.68 |
| Working Capital | 133.90M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$8.70 million and capital expenditures -$19.00 million, giving a free cash flow of -$27.70 million.
| Operating Cash Flow | -8.70M |
| Capital Expenditures | -19.00M |
| Free Cash Flow | -27.70M |
| FCF Per Share | -$0.30 |
Full Cash Flow StatementMargins
Gross margin is 69.89%, with operating and profit margins of -10.51% and -15.20%.
| Gross Margin | 69.89% |
| Operating Margin | -10.51% |
| Pretax Margin | -14.74% |
| Profit Margin | -15.20% |
| EBITDA Margin | -3.20% |
| EBIT Margin | -10.51% |
| FCF Margin | n/a |
Dividends & Yields
Myriad Genetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.42% |
| Shareholder Yield | n/a |
| Earnings Yield | -18.61% |
| FCF Yield | -4.05% |
Dividend DetailsAnalyst Forecast
The average price target for Myriad Genetics is $20.17, which is 171.83% higher than the current price. The consensus rating is "Hold".
| Price Target | $20.17 |
| Price Target Difference | 171.83% |
| Analyst Consensus | Hold |
| Analyst Count | 16 |
| Revenue Growth Forecast (5Y) | 5.70% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on March 26, 2009. It was a forward split with a ratio of 2:1.
| Last Split Date | Mar 26, 2009 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Myriad Genetics has an Altman Z-Score of 3.35 and a Piotroski F-Score of 3.
| Altman Z-Score | 3.35 |
| Piotroski F-Score | 3 |